Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165753 | 0.84 | CYP1A2 (0.31) | NR4A2 | |
| SCHEMBL2076088 | 0.81 | NR4A2 (0.35) | NR4A2 | |
| SCHEMBL4800668 | 0.79 | HPGD (0.34) | NR4A2HPGD | |
| SCHEMBL4159114 | 0.78 | NR4A2 (0.33) | NR4A2HPGD | |
| SCHEMBL4161630 | 0.77 | NR4A2 (0.31) | NR4A2 | |
| SCHEMBL2075029 | 0.76 | JAK2 (0.42) | NR4A2HPGD | |
| SCHEMBL2075809 | 0.75 | NPC1 (0.38) | NR4A2HPGD | |
| SCHEMBL4160113 | 0.74 | MAPT (0.37) | NR4A2HPGD | |
| SCHEMBL4163033 | 0.73 | ALDH1A1 (0.54) | HPGD | |
| SCHEMBL4172292 | 0.72 | PIK3CG (0.37) | NR4A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | NR4A2 1952/4885HPGD 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.